Unknown

Dataset Information

0

Triple-negative breast cancer.


ABSTRACT: Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-called basaloid tumors are not always synonymous with TN tumors; they differ in the fact that they express different molecular markers, have a higher histologic grade, and have a worse prognosis. Clinically they occur in younger women as interval cancer, and the risk of recurrence is higher within the first 3 years. Distant recurrences in the brain and visceral metastases are more common than in hormone receptor-positive tumors. Therapeutically, despite being highly chemosensitive, their progression-free time is generally short. In terms of chemotherapeutic treatment, anthracyclines and taxanes are useful drugs, and high response rates have been described for the combination of ixabepilone-capecitabine and platinums. The combination with antiangiogenic drugs has also proven useful. A group of new drugs, poly-(ADP-ribose)-polymerase inhibitors, showed favorable results in TN tumors with BRCA mutation. There are currently several ongoing studies with new drugs including epidermal growth factor receptor inhibitors, c-kit inhibitors, Raf/Mek/Map kinase inhibitors and mTOR inhibitors.

SUBMITTER: Chacon RD 

PROVIDER: S-EPMC2972557 | biostudies-literature | 2010

REPOSITORIES: biostudies-literature

altmetric image

Publications

Triple-negative breast cancer.

Chacón Reinaldo D RD   Costanzo María V MV  

Breast cancer research : BCR 20101022


Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-called basaloid tumors are not always synonymous with TN tumors; they differ in the fact that they express different molecular markers, have a higher histologic grade, and have a worse prognosis. Clinically they occur in younger women as interval cancer, and the risk of recurrence is higher  ...[more]

Similar Datasets

| S-EPMC4914340 | biostudies-literature
| S-ECPF-ERAD-113 | biostudies-other
| S-ECPF-GEOD-46581 | biostudies-other
| S-EPMC5995333 | biostudies-literature
| S-EPMC3856060 | biostudies-literature
| S-EPMC8705248 | biostudies-literature
| S-EPMC4102808 | biostudies-other
| S-EPMC3364210 | biostudies-other
| S-EPMC8459207 | biostudies-literature
| S-EPMC7136496 | biostudies-literature